Vote Scores
Filings read through

How funds voted at CRISPR THERAPEUTICS AG

Ticker
CRSP
SEC company number
1674416
Filers reporting
630, year to 30 June 2026
Latest meeting on file
Meetings on file
3

In the year to 30 June 2026, 630 filers on Form N-PX reported votes at CRISPR THERAPEUTICS AG. The votes fall in 2 meetings. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 1,143 marks to the ballot items, each with or against management. 72.0% of the marks are with management.

On say-on-pay, 264 of the 575 reporting filers that marked the item voted against management. This is 45.9% of the filers. Of the reported shares, 29.1% went against management. The median of the 3,799 companies on this site with a say-on-pay item is 6.6% of filers and 2.9% of reported shares.

At the meeting of 4 Jun 2026, 16 fund families have a say-on-pay position with management and 29 have a position against management.

By filers reporting in the year to 30 June 2026, CRISPR THERAPEUTICS AG was number 780 of 11,972 companies with a page and votes in that year. The number of filers reporting at CRISPR THERAPEUTICS AG rose by 19.5% from the year to 30 June 2025 to the year to 30 June 2026. At the companies on this site with filers in both years, the total of filers reporting rose by 6.0%. In all seasons on file, category COMPENSATION is 20.8% of the vote records at CRISPR THERAPEUTICS AG. At all companies on this site, it is 6.6%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 4 Jun 2026

625 filers reported votes at this meeting in the year to 30 June 2026. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Director elections

    12 nominees. 76.6% of the reported votes are for. 89 filers withheld from or voted against at least one nominee.

    3,235 vote records from 117 filers. 14 of the 109 filers that marked the item voted against management. 8 filers gave no management mark.

    • Positions of 39 fund families
    • For 31
    • Against 7
    • Split or no vote 1
    • Against management 6
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    1,343 vote records from 622 filers. 264 of the 575 filers that marked the item voted against management. 47 filers gave no management mark.

    • Positions of 46 fund families
    • For 16
    • Against 29
    • Split or no vote 1
    • Against management 29
  3. Item 3: Audit-related items (auditor ratification)

    243 vote records from 115 filers. 1 of the 107 filers that marked the item voted against management. 8 filers gave no management mark.

    • Positions of 39 fund families
    • For 38
    • Split or no vote 1
  4. Item 4: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    667 vote records from 115 filers. 0 of the 107 filers that marked the item voted against management. 8 filers gave no management mark.

    • Positions of 39 fund families
    • For 38
    • Split or no vote 1
  5. Item 5: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    1,641 vote records from 124 filers. 35 of the 114 filers that marked the item voted against management. 10 filers gave no management mark.

    • Positions of 39 fund families
    • For 22
    • Against 16
    • Split or no vote 1
    • Against management 16
  6. Item 6: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    1,189 vote records from 116 filers. 3 of the 108 filers that marked the item voted against management. 8 filers gave no management mark.

    • Positions of 39 fund families
    • For 37
    • Against 1
    • Split or no vote 1
    • Against management 1
  7. Item 7: OTHER: management items

    The company's items in this category are shown together, because filers word and number them differently.

    65 vote records from 19 filers. 0 of the 18 filers that marked the item voted against management. 1 filer gave no management mark.

    • Positions of 3 fund families
    • For 1
    • Split or no vote 2

Positions of the fund families at the meeting of 4 Jun 2026

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at CRISPR THERAPEUTICS AG, meeting of 4 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familySay-on-pay
AllianceBernsteinAgainst, against management
AllspringAgainst, against management
American BeaconFor
American CenturyFor
BairdAgainst, against management
BlackRock and iSharesFor
BNY MellonFor
Brighthouse FundsFor
Capital Group and American FundsAgainst, against management
Charles SchwabAgainst, against management
Columbia ThreadneedleAgainst, against management
DimensionalAgainst, against management
DWSAgainst, against management
EquitableAgainst, against management
Federated HermesAgainst, against management
FidelityAgainst, against management
First TrustAgainst, against management
Franklin TempletonAgainst, against management
Global XAgainst, against management
Goldman SachsAgainst, against management
Guggenheim and RydexAgainst, against management
InvescoAgainst, against management
J.P. MorganFor
Jackson National fundsFor
John Hancock and ManulifeAgainst, against management
Lincoln FinancialFor
Lord AbbettFor
MassMutualFor
Morgan Stanley, Eaton Vance and CalvertAgainst, against management
NationwideAgainst, against management
Natixis and Loomis SaylesAgainst, against management
Neuberger BermanAgainst, against management
Northern Trust and FlexSharesAgainst, against management
Nuveen and TIAAAgainst, against management
Pacific Life fundsFor
PGIM and PrudentialAgainst, against management
PIMCOAgainst, against management
PrincipalSplit
ProShares and ProFundsAgainst, against management
Russell InvestmentsAgainst, against management
SEIAgainst, against management
State Street and SPDRFor
T. Rowe PriceFor
VanguardFor
VoyaFor
WisdomTreeFor

Every meeting on file

Meetings of CRISPR THERAPEUTICS AG, from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 2026625745.9%
year to 30 June 2025516760.0%
year to 30 June 2024538748.8%

Say-on-pay, season by season

Say-on-pay at CRISPR THERAPEUTICS AG: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 202663045.9%29.1%
year to 30 June 202552760.0%23.1%
year to 30 June 202454248.8%withheld
CRISPR THERAPEUTICS AG and the median of companies on this site, year to 30 June 2026
Say-on-payThis companyMedian of companies on this site
Filers against management45.9%6.6%
Reported shares against management29.1%2.9%

The median covers 3,799 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at CRISPR THERAPEUTICS AG by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS7,21038.2%
SECTION 14A SAY-ON-PAY VOTES2,98515.8%
AUDIT-RELATED5442.9%
CAPITAL STRUCTURE1,1576.1%
COMPENSATION3,92020.8%
CORPORATE GOVERNANCE2,77014.7%
OTHER2661.4%

The record at the SEC

Each link loaded on .

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

How embedding works. It is free. Keep the link in the card and the link line under it.

Cite this page

Vote Scores. How funds voted at CRISPR THERAPEUTICS AG. https://votescores.com/company/crispr-therapeutics-ag/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of CRISPR THERAPEUTICS AG are on file?
3 meetings are on file, from 30 May 2024 to 4 Jun 2026. 3 meetings have 20 or more reporting filers and have their own page.
Did filers report proposals from security holders at CRISPR THERAPEUTICS AG?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2026. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. CRISPR THERAPEUTICS AG reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list CRISPR THERAPEUTICS AG, grouped by company. The name is the most common spelling among filers. The ticker and the SEC company number come from the SEC company tickers file, matched on the exact name. The filers wrote the filings. Filings read through .